3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
Advertisement
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
SXTP 60 Degrees Pharmaceuticals Inc
1,229
$0.345
$0.0591
(20.67%)
| Watchers | 1,229 |
| 52-Wk Low | $0.2011 |
| 52-Wk High | $8.65 |
| Market Cap | $4.21M |
| Volume | 2.12M |
| 52-Wk High | $8.65 |
| 52-Wk Low | $0.2011 |
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Rating Reiterated by HC WainwrightTicker Report • 2 months ago
HC Wainwright reaffirmed their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP - Free Report) in a research report released on Wednesday morning, Benzinga reports. HC Wainwright...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Study to be conducted by North Carolina State University in 2024Standard of care fails in 20 percent of cases and drug resistance is a problemStandard of care is expensive WASHINGTON, April 03...
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP Get Free Report) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 65,500...
Central Bank & Trust Co. reduced its position in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP Free Report) by 23.7% in the 4th quarter, according to the company in its most recent Form 13F...
WASHINGTON, March 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP, SXTPW) ( 60 Degrees Pharmaceuticals or the Company ), a pharmaceutical company focused on...
Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitalsTafenoquine's presumed mode of action against C. auris is differentiated from standard of care...
To lead U.S. commercial relaunch of ARAKODA (tafenoquine) for malaria preventionWill support Company plan to expand clinical research strategy in tick-borne diseases beyond acute babesiosis...
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering PR...
WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ( 60 Degrees Pharmaceuticals or the Company ), specialists in developing and marketing new...